Navigation Links
Sigma-Aldrich(R) Licenses RAFT Polymerization Technology From CSIRO(R)
Date:3/11/2010

RAFT technology is a living radical polymerization process and a powerful method for the synthesis of tailor-made polymers with predetermined molecular weights and highly complex architectures.  Such designer polymers can be used to prepare materials with unique properties controlled by their nanometer scale molecular architecture in industries such as biomedical, specialty chemical and personal care.  The RAFT method is applicable to a wide range of monomers and experimental conditions and its utility is reflected in more than 200 patents related to RAFT technology.  Sigma-Aldrich will manufacture and distribute the critical components of RAFT polymerization, RAFT agents, to enable companies and research organizations to undertake further research into this groundbreaking technology.

"The RAFT technology is creating global impact and has been licensed by a range of Australian and multinational companies," added Kate Dawson, CSIRO's business development manager, RAFT.  "Making RAFT agents available from Sigma-Aldrich is a big step toward enabling researchers to achieve the major improvements that RAFT can bring in areas such as coatings, biomaterials, polymer synthesis and personal care."

Sigma-Aldrich currently offers seven RAFT agents that can be supplied in quantities from standard 1g an
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
2. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
3. Omnyx Licenses Olympus Digital Pathology Patents
4. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
5. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
6. TenX Biopharma Licenses Zanolimumab From Genmab
7. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
8. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
9. SCOLR Pharma, Inc. Licenses Dietary Supplements
10. StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke
11. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled ... by the time they turn age 35 a quarter of all women in the U.S. will ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, who ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: ... there is a large gap between the unmet health priorities in the region ... outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone conference, ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud ... Post Graduate Teaching Award on behalf of the department of Family Practice. , “This ... field to be practicing in. The technology is changing so rapidly and we are ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest regarded provider ... Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings detect early ... affordable and accurate and run about an hour long with same day results. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects ... medical field to access and use this “Big Data” to improve health and cut ... Executive Officer of the Mount Sinai Health System in New York City. Physicians will ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5
... Life Sciences has submitted an application with the Drug ... phase-1 clinical trials of its new drug Suvn-502 for ... ,'Treatment for Alzheimer's disease and Schizophrenia is ... to discover drugs that address significant unmet medical needs,' ...
... Nepalese doctors has developed a drug that is more ... reported Friday . ,The drug also costs ... Organization (WHO), reported The Himalayan Times daily.Doctors at the ... typhoid patients. ,,The team compared the effectiveness ...
... 1,763 food shipments from India, 1,480 from Mexico and 1,368 ... year . ,Some of India's spices, seeds and ... found too filthy to eat. Chinese products like seafood, bean ... has reported. ,,But the FDA did not reveal the ...
... for the high-tech dental lasers used mainly to prepare cavities ... conducted by researchers in Austria, these advanced dental lasers can ... study credits the progress of miniaturized, flexible fiber tips for ... treatment. ,Dr. Ulrich Schoop and a team of ...
... on the Yamuna River that flows past India's capital, it's easy ... surface by rotting sewage -- and that's after at least ... ,Now, with New Delhi to host the Commonwealth Games in ... built on the stinking river's banks, India must do in three ...
... the end of the last century death rates from breast ... Long waiting lists, resulting in delayed diagnosis and treatment, were ... is failing breast cancer patients and needs to be reviewed ... brought in the 2 week wait rule which stipulated that ...
Cached Medicine News:Health News:US Rejects More Food from India Than from Any Other Country 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 3Health News:Two Week Wait Rule Not Working With Breast Cancer Patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: